References
- Chu EA, Kim YJ. Laryngeal cancer: diagnosis and preoperative work-up. Otolaryngologic Clin North Am 2008;41:673–95.
- Cosetti M, Yu GP, Schantz SP. Five-year survival rates and time trends of laryngeal cancer in the US population. Arch Otolaryngol Head Neck Surg 2008;134:370–9.
- Weichert W, Denkert C, Noske A, Darb-Esfahani S, Dietel M, Kalloger SE, et al. Expression of class I histone deacetylases indicates poor prognosis in endometrioid subtypes of ovarian and endometrial carcinomas. Neoplasia 2008;10:1021–7.
- Sasaki H, Moriyama S, Nakashima Y, Kobayashi Y, Kiriyama M, Fukai I, et al. Histone deacetylase 1 mRNA expression in lung cancer. Lung Cancer 2004;46:171–8.
- Halkidou K, Gaughan L, Cook S, Leung HY, Neal DE, Robson CN. Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate 2004;59:177–89.
- Krusche CA, Wülfing P, Kersting C, Vloet A, Böcker W, Kiesel L, et al. Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis. Breast Cancer ResTreat 2005;90:15–23.
- Theocharis S, Klijanienko J, Giaginis C, Rodriguez J, Jouffroy T, Girod A, et al. Histone deacetylase-1 and -2 expression in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patients survival. J Oral Pathol Med 2011;40:706–14.
- Han Y, Zhang Y, Yang LH, Mi XY, Dai SD, Li QC, et al. X-radiation inhibits histone deacetylase 1 and 2, upregulates Axin expression and induces apoptosis in non-small cell lung cancer. Radiat Oncol 2012;7:183–8.
- Zhang B, Wang Y, Pang X. Enhanced radiosensitivity of EC109 cells by inhibition of HDAC1 expression. Med Oncol 2012;29:340–8.
- Baylin SB, Jones PA. A decade of exploring the cancer epigenome-biological and translational implications. Nat Rev Cancer 2011;11: 726–34.
- Kouzarides T. Histone acetylases and deacetylases in cell proliferation. Curr Opin Genet Dev 1999;9:40–8.
- Heo K, Kim JS, Kim K, Kim H, Choi J, Yang K, et al. Cell-penetrating H4 tail peptides potentiate p53-mediated transactivation via inhibition of G9a and HDAC1. Oncogene 2013;32:2510–20.
- Singh TR, Shankar S, Srivastava RK. HDAC inhibitors enhance the apoptosis – inducing potential of TRAIL in breast carcinoma. Oncogene 2005;24:4609–23.
- Kim HR, Kim EJ, Yang SH, Jeong ET, Park C, Lee JH, et al. Trichostatin A induces apoptosis in lung cancer cells via simultaneous activation of the death receptor-mediated and mitochondrial pathway? Exp Mol Med 2006;38:616–24.
- Emanuele S, Lauricella M, Carlisi D, Vassallo B, D’Anneo A, Di Fazio P, et al. SAHA induces apoptosis in hepatoma cells and synergistically interacts with the proteasome inhibitor Bortezomib. Apoptosis 2007;12:1327–38.
- Insinga A, Monestiroli S, Ronzoni S, Gelmetti V, Marchesi F, Viale A, et al. Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med 2005;11:71–6.
- Murakami K, Matsubara H, Hoshino I, Akutsu Y, Miyazawa Y, Matsushita K, et al. CHAP31 induces apoptosis only via the intrinsic pathway in human esophageal cancer cells. Oncology 2010;78:62–74.
- Camphausen K, Cerna D, Scott T, Sproull M, Burgan WE, Cerra MA, et al. Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid. Int J Cancer 2005;114:380–6.